Optimal dosing for targeted therapies in oncology: Drug development cases leading by example

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1318-1324

  Sachs, Jeffrey R ^a   Mayawala, Kapil ^a   Gadamsetty, Satvik ^a   Kang, Soonmo Peter ^a   De Alwis, Dinesh P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CRIZOTINIB; DECITABINE; GALUNISERTIB; IDELALISIB; PEMBROLIZUMAB; VISMODEGIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; BASAL CELL CARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TUMOR VOLUME; ANIMAL; DOSE RESPONSE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84987837993     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1295     Document Type: Review

References (42)

1. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
2. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65.
3. Postel-Vinay S, Arkenau HT, Olmos D, Ang J, Barriuso J, Ashley S, et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8.
4. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007;13:6719-26.
5. Mehrotra N. Dose selection for small molecule oncology drugs: present state and future considerations [abstract]. In: Proceedings of the FDA-AACR Meeting (Dose-finding of small molecule oncology drugs); 2015 May 18-19; Washington, DC. Philadelphia (PA): AACR; 2015. Available from: https://youtu.be/XqLYFrFLtdE.
6. Kurzrock R, Sherman S, Ball D, Forastiere A, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6.
7. Elisei R, Schlumberger M, Muller SP, Schoffski P, Shah M, Bose MS, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46.
8. Sinha V. Model informed drug development: is there a need to repaint the canvas? [abstract]. In: Proceedings of the 23rd Annual Meeting of the Population Approach Group in Europe; 2014 Jun 10-13; Alicante, Spain. Abstract nr C-12.
9. U.S. Food and Drug Administration. Approval letter (application number: 203756Orig1s000) [PDF on the internet].Silver Spring (MD): U.S. Food and Drug Administration; 2012 [cited 2015 Sep 11].Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/203756Orig1-s000Approv.pdf.
10. Penel N, Adenis A, Clisant S, Bonneterre J. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. Invest New Drugs 2011;29:1414-9.
11. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
12. Toloi DDA, Jardim DLF, Hoff PMG, Riechelmann RSP. Phase I trials of antitumour agents: fundamental concepts. eCancer 2015;9:1-10.
13. Tomaszewski JE, Doroshow JH. Preclinical development of molecularly targeted agents in oncology. In:Kaufman HL, Wadler S, Antman K, editors. Molecular targeting in oncology. Totowa, NJ: Humana Press; 2008. p. 707-22.
14. Zohar S, Resche-Rigon MF, Chevret S. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clin Trials 2013;10:414-21.
15. Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials 2014;11:319-27.
16. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
17. PharmaPendium [database on the internet]. Amsterdam (The Netherlands): Elsevier. c2015. Available from: http://www.pharmapendium.com.
18. Thomson Reuters Integrity [database on the internet]. New York (NY): Thomson Reuters. c2015. Available from: https://integrity.thomson-pharma.com/integrity/xmlxsl.
19. Google [search engine on the Internet]. Mountain View (CA): Google.. Available from: https://www.google.com.
20. Google Scholar [search engine on the Internet]. Mountain View (CA): Google. Available from: https://scholar.google.com/.
21. RxList.com [database on the Internet]. San Clemente (CA): RxList Inc. c2015. Available from: http://www.rxlist.com/script/main/hp.asp.
22. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-73.
23. Jardim DL, Hess K, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res 2014;20:281-8.
24. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
25. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015;21:4286-93.
26. Joseph RW, Gandadhar TC, Puzanov I, Robert C, Hamid O, Dummer R, et al. Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. J Clin Oncol 33, 2015 (suppl; abstr 3068).
27. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-7.
28. Ramanathan S, Jin F, Sharma S, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clin Pharmacokinet 2015;55:33-45.
29. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
30. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91.
31. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
32. Rudin CM. Vismodegib. Clin Cancer Res 2012;18:3218-22.
33. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
34. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 2012;340:549-57.
35. Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J 2013;15:354-66.
36. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008;44:142-50.
37. Gueorguieva I, Cleverly A, Stauber A, Pillay NS, Rodon J, Miles C, et al. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 based on a PK/PD model. Br J Clin Pharmacol 2014;77:796-807.
38. Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, et al. The signature program: bringing the protocol to the patient. Clin Pharmacol Ther 2015;98:124-6.
39. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
40. Bruno R, Mercier F, Claret L. Evaluation of tumor size response metrics to predict survival in oncology clinical trials. Clin Pharmacol Ther 2014;95:386-93.
41. Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 2013;31:2110-4.
42. American Association for Cancer Research. In: Proceedings of the FDA-AACR Meeting (Dose-finding of small molecule oncology drugs); 2015 May 18-19; Washington, DC. Philadelphia (PA): AACR; 2015. Available from: http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/dose-finding-of-small-molecule-oncology-drugs.aspx#1-2.